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Abstract
Background: Most incisions following surgery heal by primary intention, with the edges of the wound apposed
with sutures or clips. However, some wounds may break open or be left to heal from the bottom up (i.e. healing by
secondary intention). Surgical Wounds Healing by Secondary Intention (SWHSI) are often more complex to manage,
and require additional treatments during the course of healing. There is significant uncertainty regarding the best
treatment for these complex wounds, with limited robust evidence regarding the clinical and cost-effectiveness of
different dressings and treatments; one such treatment is Negative Pressure Wound Therapy (NPWT) which is
frequently used in the management of SWHSI. Previous randomised controlled trials (RCTs) of NPWT have failed
to recruit to time and target, thus we aimed to conduct a pilot RCT to assess the feasibility of conducting a future,
full-scale RCT.
Methods: This pilot RCT will test the methods and feasibility of recruiting, randomising, and retaining participants
into a larger trial of NPWT verses usual care for patients with SWHSI. Participants will be randomised to receive
either NPWT or usual care (no NPWT) and will be followed up for 3 months.
Discussion: This study will provide a full assessment of methods for, and feasibility of, recruiting, randomising, and
retaining patients with SWHSI in a trial of NPWT versus usual care. On the basis of this pilot trial, a full trial may be
proposed in the future which will provide additional, robust evidence on the clinical and cost-effectiveness of
NPWT in the management of SWHSI.
Trial registration: Clinical Trial Registry: ISRCTN12761776, registered on 10 December 2015 – retrospective
registration.
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Background
A substantial number of surgical operations are con-
ducted in the NHS each year, with most involving an
incision [1]. The edges of these incisions are often held
together whilst healing occurs (primary closure); however,
many surgical wounds break open or are left open to heal
(healing by secondary intention). Surgical Wounds Heal-
ing by Secondary Intention (SWHSI) present a significant
management challenge as they may remain open for
many months and/or require multiple, additional treat-
ments (e.g. prolonged hospitalisation, reoperation, in-
fection management) [2]. As a result, management of
SWHSI presents a significant financial burden to the
NHS and also impacts substantially on patients’ quality
of life.
There is much research evidence available to guide
the management of SWHSI; however, as NICE reflected
in their 2012 guidelines [3], there is a need for robust,
experimental evidence to assess the most clinical and
cost-effective dressings and treatments for surgical site
management. Negative Pressure Wound Therapy (NPWT)
has become a widely used intervention for SWHSI, albeit
more frequently within acute rather than community
settings [4]. NPWT devices apply negative pressure to a
wound via a dressing which theoretically promotes
wound healing by removing exudate and reducing in-
fections [5]. The device is generally only used for part
of the SWHSI treatment pathway rather than to the
point of healing.
A Cochrane Review in 2015 [6] specifically investi-
gated NPWT as a treatment for SWHSI; however, the
review found only two trials eligible for inclusion. On
the basis of this limited evidence and the fact that
NPWT is widely used in the NHS to treat SWHSI, there
is an urgent need to assess the effectiveness of this inter-
vention in this specific patient population.
Previous trials of NPWT have struggled to recruit [7,
8] and so it would seem to be essential, before embark-
ing on a full RCT, to assess the feasibility of conducting
such research. Our study, therefore, seeks to ascertain
the feasibility of conducting a full RCT in this area, spe-
cifically investigating the appropriate methods to use to
collect meaningful and worthwhile data.
Methods
Design
This study is a pilot RCT conducted in three centres to
test the methods and feasibility of a full RCT of NPWT
compared with usual care (no NPWT) for SWHSI.
Informed consent will be obtained from each patient
prior to randomisation into the study. Eligible patients
will be individually randomised to one of two treatment
arms: (1) NPWT or (2) usual care (no NPWT).
The key objectives of this trial are to determine the
methods and feasibility of conducting a larger RCT in
this area. Specifically, this pilot trial will assess:
1. Recruitment rate including willingness of
participants to be randomised and whether
recruitment is influenced by wound location or
other factors, e.g. associated surgical speciality
2. Clinician willingness and ability to recruit and
randomise participants
3. Testing of inclusion and exclusion criteria
4. Fitness for purpose of data collection methods
including across and between care settings
5. Ability of sites and clinicians to supply NPWT
to intervention participants in a timely fashion,
irrespective of care setting, and to assess any
training requirements
6. Ability of community staff to manage participants
randomised to NPWT
7. Suitability of method of outcome ascertainment
8. Adequacy of duration of follow-up
9. Rates of withdrawal from treatment, response rates
to questionnaires, attrition from the trial, and likely
rates of missing data for outcomes
10.Assessment of feasibility of blinding outcome
assessors to treatment allocation
11.Acceptability of trial documentation to nurses
collecting study data in addition to treating patients
12.The primary outcome for this pilot trial will be
time to complete wound healing (full wound
epithelialisation). However, this pilot study is not
looking to detect a treatment effect but to
determine the ability to recruit to, and collect
high-quality data in, a full RCT. Secondary
outcomes and methods of data collection are
summarised in Table 1.
Participants will be followed up every 1–2 weeks, de-
pending on feasibility, for clinical outcome assessment.
Participant-completed questionnaires will be completed
at baseline, 2 weeks, 1 month, and 3 months post ran-
domisation. Participants will be followed from random-
isation to trial exit, which is deemed to be 3 months after
randomisation, or loss to follow-up or death (if before this
time). Participant flow through the trial and the schedule
of study activities are displayed in Fig. 1.
Inclusion and exclusion criteria
Inclusion
Our target population will be patients aged 18 years and
over who are able to give full informed consent and who:
are receiving care from either Hull and East Yorkshire
Hospitals NHS Trust, Leeds Teaching Hospitals NHS
Trust or Leeds Community Healthcare NHS Trust; have a
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SWHSI which could be reasonably treated with NPWT
or wound dressings; have a SWHSI which is considered
ready for NPWT (i.e. minimum 80 % viable tissue or
thin layer of slough requiring no further debridement);
and are receiving adequate nutrition (as assessed by the
senior nurse responsible for nursing care).
Exclusion
We will exclude patients who: are unable to give
informed consent; have limited life expectancy (e.g. are
undergoing end-stage palliative care); have an active
systemic infection; have already received NPWT on their
current SWHSI, are currently receiving NPWT or re-
ceived NPWT whilst in theatre for the surgery resulting in
their SWHSI; have inadequate haemostasis or are at
risk of bleeding; have chronic wounds such as pressure
or foot ulcers which are nonsurgical in origin but which
have been surgically debrided (we regard these patients
as a distinctly different subgroup); are unwilling to have
wound photographs taken; or are currently or have pre-
viously participated in a research study within the last
4 weeks.
Patients will also be excluded if they have any of the
following wound characteristics present: unclear under-
mining in the wound cavity precluding use of NPWT;
necrotic tissue or eschar; malignant tissue; exposed
blood vessels and/or organs, anastomotic sites, and/or
nerves (including cases where abdominal fascia is
Table 1 Secondary outcome measures
Secondary outcome Measured by/using
Number of patients screened Pre-Trial Screening Assessment Form
Number of patients eligible/ineligible Pre-Trial Screening Assessment Form
Appropriateness of eligibility criteria and reasons for ineligibility Pre-Trial Screening Assessment Form
Proportion of eligible patients consenting to participate (and
whether type of wound/surgical speciality impacts on this)
Consent Form and Pre-Trial Screening Assessment Form
Time between randomisation and treatment start Phase 1 Start of Treatment Form
Proportion of patients receiving randomised treatment within
48 h
Phase 1 Start of Treatment Form
Duration of Negative Pressure Wound Therapy (NPWT) Phase 1 Start of Treatment Form and End of Phase 1 Treatment Form
Factors affecting timely delivery of randomised treatment Non-immediate Use of NPWT Form
Wound dimensions Assessment of Weekly Participant Events Form
Quality and completeness of data collected for date of healing Assessment of Weekly Participant Events Form and Blinded Outcome Assessment
Form
Patient-reported health-related quality of life The Short Form (12) Health Survey (SF-12) [13]
EuroQoL (EQ-5D) [14]
Cointerventions used and rate of treatment change Investigator Baseline Case Report Form (CRF), Assessment of Weekly
Participant Events Form, Phase 1 Start of Treatment Form, Phase 1 End of
Treatment Form
Significant events (e.g. rehospitalisation, infection, reoperation) Assessment of Weekly Participant Events Form
Adverse events Adverse Event Form, Serious Adverse Event Form, Adverse Event/Serious Adverse
Event Follow-up Form
Response rates Proportion of participant self-report measures returned
Withdrawal rates Change of Status Form
Treatment change including change from NPWT for intervention
participants, reasons for changes and changes to NPWT
Surgical Wounds Dressing Change Form, End of Phase 1 Treatment Form
and Assessment of Weekly Participant Events Form
Resource use Resource Use Questionnaire (3-month Participant CRF)
Missing data rates Missing responses
Healing rates Assessment of Weekly Participant Events Form, Blinded Outcome Assessment Form
Blinded outcome assessment Blinded Outcome Assessment Form
Participant opinion on trial participation Likert Scales (3-month Participant CRF)
Self-reported wound pain Weekly text messaging
Visual Analogue Scales (baseline, 2-week, 1-month and 3-month Participant CRFs)
Brief Pain Inventory (BPI) (baseline, 2-week, 1-month and 3-month Participant CRFs)
[15]
Wound progress Photographs Wound tracings
Depth measurements
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open); or located where a vacuum seal cannot be ob-
tained (in the opinion of the treating clinician).
Recruitment
Patients will be recruited from both acute and commu-
nity settings within Hull and Leeds; however, we antici-
pate that most participants will be recruited from acute
settings. The pilot trial will be preceded by promotion of
the study with surgeons and nurses in both settings.
All patients who experience a SWHSI (at any point
following surgery) will be screened for trial eligibility
by their clinical care team. Potential participants will
then be approached with further details of the study by
surgical or nursing staff (clinical or research) during
ward rounds, routine care or home visits, depending on
patient circumstance.
Potential participants will be provided with a patient in-
formation sheet and will be given at least 24 h to consider
their involvement in this research. Patients will then have
the opportunity to discuss the study with the research
team prior to completing the study consent form.
We aim to randomise 50 patients for this pilot trial
over a 7-month period. As evidenced by Edwards et al.
in 2002 [9], nonconditional, monetary incentives are
shown to double response rates to postal questionnaires;
participants will, therefore, be sent a £5 unconditional
cash token with their final questionnaire (at 3 months
post randomisation). Participants who consent to receiv-
ing weekly text messages, and provide a mobile telephone
number to facilitate this, will also be reimbursed £5 to
cover any costs incurred in responding to weekly pain
assessment text messages.
Fig. 1 Participant flowchart and schedule of activity. Outlining participant flow through the study and outcome measurement completion time points
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Randomisation
Patients will be randomised into one of two arms: (1)
NPWT or (2) usual care (no NPWT) on a 1:1 basis. To
remove the potential for selection bias, allocations will
be concealed through use of a central randomisation ser-
vice implemented by an independent member of staff at
the York Trials Unit, University of York. Study sites will
contact a remote telephone service to provide details of
the participant and to receive details of the treatment al-
location. Randomisation will be conducted using a preg-
enerated sequence of random permuted blocks with
stratification by wound area (<28 cm2, ≥28 cm2).
Due to the nature of the intervention it is not pos-
sible to blind participants or health care professionals
to trial treatment. Feasibility of blinded outcome as-
sessment of healing will, however, be assessed as part of
this trial. Assessors blind to trial treatment allocation
will be provided with copies of wound photographs and
will be asked to confirm whether (1) they deem the
wound to be healed (full wound epithelialisation), and
(2) they believe they know the allocated treatment
allocation.
Sample size
As this is a pilot trial, and the primary objective is to
determine measures of feasibility and acceptability rather
than to detect a treatment effect, a formal sample size
calculation has not been conducted. We will, however,
aim to randomise approximately 50 patients as a means
to assess recruitment, randomisation, and retention of
participants.
Interventions
Experimental group: Negative Pressure Wound Therapy
There are several NPWT systems available within the
NHS; however, for the purposes of this trial we originally
permitted the use of the following CE-marked products
currently used in acute and community settings in Hull
and Leeds: (1) V.A.C.® (KCI), and (2) Renasys® (Smith
and Nephew). A further device (PICO® – Smith and
Nephew) has subsequently been added as a trial device
in a recent protocol amendment.
NPWT treatments consist of a vacuum pump into
which a disposable plastic canister is placed to enable
wound exudate to be collected. The canister is attached
to pressure resistant tubing to create an airtight seal.
The wound to be treated is filled with a suitable dressing
(foam or gauze) along with a nonadherent layer, if
required, to protect blood vessels or organs and/or to
prevent dressing adherence.
In this trial, the choice of machine and duration of
NPWT will be decided by the treating health profes-
sional in conjunction with the participant and nurse.
Pressure cycles and dressing change frequency will be
completed as per standard practice and recorded. The
only stipulation with regards NPWT use is that this
must be clinically appropriate. When not being treated
with NPWT, participants in this arm of the trial will be
treated as per usual care.
Comparator group: Usual Care (no NPWT)
The control group participants will receive usual care.
This is likely to be wound dressings which will be chan-
ged every 1–3 days, or sometimes less frequently, as de-
termined by the treating surgeon or nurse in line with
standard practice. The trial protocol does not stipulate
the type of dressings which should be used as part of
usual care as there is no evidence to suggest that any
one dressing is more clinically or cost-effective than
another. Control dressings are, therefore, selected by the
clinician on the basis of the dressing most appropriate
for the patient. The types of primary and secondary
dressings used, and the frequency of dressing change,
will be recorded throughout the trial.
Statistical analysis
A full statistical analysis plan for primary and secondary
analyses will be generated prior to completion of recruit-
ment for this trial. The Trial Management Group and
the Data Monitoring and Ethics Committee (DMEC) will
review this prior to commencement of outcome analysis.
During the trial regular reports will be prepared for the
DMEC with regards data quality and safety.
The analyses will be conducted following the principles
of intention-to-treat. All outcomes will be summarised
using descriptive statistics overall and by trial group.
The primary clinical outcome of time to healing will
be presented using Kaplan-Meier curves for interest
only, recognising that the study is not powered to detect
clinically important treatment effects. This analysis will
be conducted using blinded outcome assessment dates
of healing if possible. A Cox proportional hazards re-
gression analysis will be conducted, subject to sufficient
data, to investigate the inclusion of additional covari-
ates shown to be important in an earlier SWHSI cohort
(e.g. contamination level of surgery, wound infection),
along with the stratification factor (baseline wound size)
used in the randomisation for this trial. The impact of
SWHSI history, location of SWHSI on the body and infec-
tion at any time during follow-up (as a time dependent
covariate) will also be explored.
Cost-effectiveness will be explored by calculating a
mean total cost per trial arm using resource use and
relevant unit costs for each participant. Should suffi-
cient data be available, EuroQoL 5 dimensions (EQ-5D)
questionnaire data will be used to calculate a mean
quality-adjusted life year (QALY) for each trial arm.
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Patient and Public Involvement
Patient and Public Involvement (PPI) comes from a pa-
tient user group comprising 10 members who have con-
tributed to the design and conduct of the study. This
has included input on the outcomes collected, study
documentation design and wording, and will include in-
put into planned dissemination of research findings. The
group members are patients who have participated in an
earlier SWHSI cohort study. PPI members will be appro-
priately reimbursed for their participation in line with
INVOLVE guidelines [10].
The Trial Steering and Data Monitoring and Ethics
Committees
As this is a pilot trial, the study will be monitored closely
by an in-house Trial Management Team who will meet
on a monthly basis. A Trial Steering Committee will not
be convened for this trial.
A Data Monitoring and Ethics Committee (DMEC) will
be formed to routinely review data, participant safety, and
protocol compliance. The committee will consist of inde-
pendent members: a statistician; two clinicians; and a PPI
representative who will meet, at minimum, once prior to
study commencement and once during the study duration.
Forecast execution dates
The set-up of the trial commenced on 8 October 2015, fol-
lowing Research Ethics Committee (REC) approval, and
was completed in March 2016. Recruitment of participants
commenced on 20 November 2015 and will be completed
on 30 June 2016. Follow-up for the trial commenced in
December 2015 and will continue until 30 September
2016. Data analysis will commence in October 2016. The
final report associated with this programme grant will be
submitted in February 2017.
Protocol changes
Protocol amendments made since the start of this trial
are detailed in Table 2.
The study protocol has been written in accordance
with the Consolidated Standards of Reporting Trials
(CONSORT) statement [11] and the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
checklist [12], as provided in Additional file 1.
Discussion
The proposed trial will explore methods for, and feasibility
of, completing a full RCT to assess clinical and cost-
effectiveness of NPWT for treatment of SWHSI compared
with usual care. As would be expected with a feasibility
trial, some barriers have been identified which may impact
on recruitment and time to completion of the pilot or
larger RCT in the future.
Engagement of sites
During the set-up of the trial, the research sites have
worked closely with their clinical colleagues to promote
the trial. Promotion included contact with specialist
teams, letters to surgeons, and posters advertising the
study to clinical staff. Despite these efforts engagement
of surgical and clinical colleagues has been mixed which
has resulted in slower than anticipated recruitment.
Continued efforts at a local level have helped to alleviate
the lack of engagement as the trial has progressed result-
ing in an improvement in recruitment rate. Substantial
work during set-up, and use of additional strategies to
engage clinical staff should, however, be explored ahead
of commencement of a larger RCT.
Governance issues
Governance delays arose in one NHS trust due to circum-
stances outside of the trial’s control. This subsequently
delayed opening of two colocated study sites, which im-
pacted upon recruitment rate in the early stages of the
trial. Despite this reduced recruitment in the early stages
of the trial, recruitment has subsequently increased in all
trusts, with the study meeting the target monthly recruit-
ment in the following 4 months.
Trial status
At the time of submission the trial is open to recruitment.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 119 kb)
Table 2 Protocol amendments made following commencement
of the trial
Aspect of the trial Amendment made
Wound measurements Depth measurement will be conducted by
swab or probe
Adverse events Serious, related, and ongoing events will be
followed up for 1 month after trial exit
Clarification of definitions of unplanned and
prolonged hospitalisation
Intervention/control Frequency of surgical wound dressing changes
will be recorded
Addition of further trial device (PICO® – Smith
and Nephew)
Study processes Patients who have their reference wound
amputated will continue to be followed
up for participant-reported measures
Patient and Public
Involvement (PPI)
Patients in the SWHSI trial will be approached
at the end of their trial involvement, with
regards involvement in a PPI group.
SWHSI surgical Wounds Healing by Secondary Intention
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